Longevity Next

Trial

TAME: Trial Design, Endpoints, and Status Tracker

Source-reviewed Last reviewed: 2026-08-02
StatusNOT_YET_INITIATED SponsorAmerican Federation for Aging Research / Wake Forest University School of Medicine
LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review

Source Summary

2 reviewed sources across 1 evidence layers.

  • Official status sources2

Jump to detailed source table

Trial Snapshot

Status NOT_YET_INITIATED
Sponsor American Federation for Aging Research / Wake Forest University School of Medicine
Status last verified 2026-08-02

Executive Summary

Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.

Why It Matters

TAME is an influential geroscience trial proposal, but design, registration, launch status and results must remain separate claims.

Trial Design

Design fieldRegistered / reported valueSourceLimitation
Population Proposed older adults without diabetes AFAR and peer-reviewed design papers Proposed design may change before registration
Intervention Metformin versus placebo Peer-reviewed design papers Not evidence of efficacy

Endpoint and Readout Map

Endpoint / readoutCategorySourceWhat it supportsLimitation
Composite of major age-related outcomes Proposed clinical composite Peer-reviewed design papers The intended geroscience trial question No registered protocol or result at cutoff

Results and Publication Context

Status boundary

No TAME results

The approved sources do not support describing TAME as initiated or reporting TAME outcomes.

Timeline / Milestones

  1. Status verified

Source Posture

Verified 2026-08-02

Official status

AFAR describes launch funding as still needed; registry search found no TAME-specific record.

Evidence / Claim Boundary

Boundary

Design is not evidence

A proposed randomized design does not establish metformin efficacy, healthspan benefit or lifespan benefit.

What This Can Support

Proposal

Supported

TAME is designed to test a composite clinical-outcome geroscience hypothesis.

What This Does Not Prove

No result

Not established

Metformin is not established as an anti-aging treatment.

Detailed Sources

View detailed source table

Official status sources

SourceTypeSupportsLimitationLink
AFAR TAME overview Official program page Current program description and funding/launch posture Sponsor description is not efficacy evidence Open source
ClinicalTrials.gov search Registry search No exact TAME registry record found at cutoff Search absence is not regulatory rejection Open registry search

Confidence / Methodology

Confidence

Editorial status

Editorial review complete; source freshness checked

Methodology scope

Evidence separation

Status is verified against the approved official-source cutoff. Proposed design is not treated as an active protocol or result.

Source freshness

Last reviewed

2026-08-02

Opens in a new tab